Information Provided By:
Fly News Breaks for January 11, 2016
PACB
Jan 11, 2016 | 14:58 EDT
Piper Jaffray analyst William Quirk said the 49 Sequels orders Pacific Biosciences reported for Q4 were above his projection of 10 orders and topped the 47 total orders he exepcted for this quarter through the second quarter of 2016. Also, commentary regarding a Sequel ramp in the second half of the year should not be surprising given management's past comments that Sequel volume will be constrained in the first half due to manufacturing and chip supply, Quirk said. The analyst keeps an Overweight rating and $9 price target on Pacific Bio shares.
News For PACB From the Last 2 Days
There are no results for your query PACB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.